148983-23-7

Basic information

• Product Name: Carbamic acid, [(2R)-2,3-dihydroxypropyl]-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, [(2R)-2,3-dihydroxypropyl]-, 1,1-dimethylethyl ester (9CI);(R)-tert-butyl (2,3-dihydroxypropyl)carbamate
• CAS NO: 148983-23-7
• Molecular Formula: C₈H₁₇NO₄
• Molecular Weight: 191.22488
• Product Categories: N-BOC
• Mol File: 148983-23-7.mol
• Article Data: 11

Chemical Properties

• Melting Point: 49 °C
• Boiling Point: 361.6±32.0 °C(Predicted)
• Appearance: /
• Density: 1.136±0.06 g/cm3(Predicted)
• PKA: 12.19±0.46(Predicted)
• CAS DataBase Reference: Carbamic acid, [(2R)-2,3-dihydroxypropyl]-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [(2R)-2,3-dihydroxypropyl]-, 1,1-dimethylethyl ester (9CI)(148983-23-7)
• EPA Substance Registry System: Carbamic acid, [(2R)-2,3-dihydroxypropyl]-, 1,1-dimethylethyl ester (9CI)(148983-23-7)

Safety Data

• Hazardous Substances Data: 148983-23-7(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 66211-46-9 (R)-3-amino-1,2-propanediol 
• 1240036-32-1 C₁₁H₂₁NO₄ 
• 131321-84-1 (R)-1-azido-2,3-dihydroxypropane 
• 148982-76-7 tert-butyl N-(2-oxiranylmethyl)carbamate 

Downstream Products

• 148983-24-8 (R)-1-<(tert-butoxycarbonyl)amino>-2-hydroxy-3-<<(4-methylphenyl)sulfonyl>oxy>propane 
• 853944-08-8 (2S)-N-tert-butoxycarbonyl-2-hydroxy-1,3-diaminopropane 
• 149057-20-5 (R)-<<(tert-butoxycarbonyl)amino>methyl>oxirane 
• 161513-47-9 (S)-<<(tert-butoxycarbonyl)amino>methyl>oxirane 

Relevant articles and documents

Synthesis and Absolute Stereochemical Reassignment of Mukanadin F: A Study of Isomerization of Bromopyrrole Alkaloids with Implications on Marine Natural Product Isolation

Synthesis of both enantiomers of mukanadin F was achieved by using a seven step synthesis. Comparison of the optical rotation data of synthetic samples to that reported for the isolated natural product determined that the absolute configuration of the natural product is 9S and not the reported 9R. Further studies established that the reported low magnitude of optical rotation in the isolated sample is due to compounds of this type undergoing isomerization and racemization under benign laboratory conditions. Additionally the synthetic methods developed were applied to synthesize mukanadins B and D.

MACROCYCLIC KINASE INHIBITORS AND THEIR USE

The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer, pain, neurological diseases, autoimmune diseases, and inflammation.

TGR5 AGONISTS

The invention relates to novel 1,4-diazepan-2-one compounds, which are TGR5 agonists and useful for the treatment of metabolic disorders, inflammatory diseases, atherosclerosis and dyslipidemias.